Key result
Advancing age (≥70 years) was independently associated with higher risks of SVT-related adverse events prior to ablation (OR 1.93) and erroneous baseline diagnosis (OR 9.14) compared to younger patients.
Why the study?
Does advancing age (≥70 years) affect the clinical presentation, treatment efficacy, safety, and long-term outcomes in patients with inducible paroxysmal SVT without pre-excitation?
Cohort (n=1,960)
No
Does advancing age (≥70 years) affect the clinical presentation, treatment efficacy, safety, and long-term outcomes in patients with inducible paroxysmal SVT without pre-excitation?
Elderly patients (≥70 years) with SVT without pre-excitation have higher risks of erroneous diagnosis, ablation failure, and procedural complications, though SVT recurrence rates are similar to younger patients.
Elderly patients with regular tachycardia merit EPS to avert misdiagnosis and inappropriate therapy; supports expanded EPS use in older adults but needs prospective validation.
AIM: To investigate the influence of increasing age on clinical presentation, treatment and long-term outcome in patients with inducible paroxysmal supraventricular tachycardia (SVT) without pre-excitation syndromes. METHODS: Clinical and electrophysiological study (EPS) data, as well as long-term clinical outcome (mean follow-up 2.4±4.0 years) were collected in patients referred for regular tachycardia with inducible SVT during EPS without pre-excitation. RESULTS: Among 1960 referred patients, 301 patients (15.4%) were aged ≥70 (70-97). In this subset, anticoagulants were prescribed in 49 patients following an erroneous diagnosis of atrial tachycardia and 14 were previously erroneously diagnosed with ventricular tachycardia because of wide QRS. Ablation was performed more frequently in patients ≥70 despite more frequent failure and complications. During follow-up, higher risks of AF, stroke, pacemaker implantation and death were observed in patients ≥70 whereas SVT recurrences were similar in both age groups. In multivariable analysis, age ≥70 was independently associated with higher risks of SVT-related adverse events prior to ablation (OR = 1.93, 1.41-2.62, p<0.001), conduction disturbances (OR = 11.27, 5.89-21.50, p<0.001), history of AF (OR = 2.18, 1.22-3.90, p = 0.009) and erroneous diagnosis at baseline (OR = 9.14, 5.93-14.09, p<0.001) as well as high rates of procedural complications (OR = 2.13, 1.19-3.81, p = 0.01) and ablation failure (OR = 1.68, 1.08-2.62, p = 0.02). In contrast, age ≥70 was not significantly associated with a higher risk of AF in multivariable analysis. CONCLUSIONS: A sizeable proportion of patients with inducible SVT without pre-excitation syndromes are elderly. These patients exhibit higher risks of erroneous tachycardia diagnosis prior to EPS as well as failure and/or complication of ablation, but similar risk of SVT recurrence. These results support performing transesophageal EPS in most patients and intracardiac EPS in selected patients. EPS may furthermore prove useful in elderly patients with regular tachycardia, mainly by avoiding treatment based on an erroneous diagnosis.
No takes yet. Share an insight, caveat, or question.
Brembilla-Perrot et al. (2018) conducted a cohort in Inducible paroxysmal supraventricular tachycardia (SVT) without pre-excitation syndromes (n=1,960). Age ≥70 years vs. Age <70 years was evaluated on SVT-related adverse events prior to ablation (OR 1.93, 95% CI 1.41-2.62, p=<0.001). Advancing age (≥70 years) was independently associated with higher risks of SVT-related adverse events prior to ablation (OR 1.93) and erroneous baseline diagnosis (OR 9.14) compared to younger patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: